PeDRA

Pediatric Dermatology Research Alliance

AD&PsO Seeking

Post-Market Surveillance of the Safety of Systemic JAK Inhibitors for Dermatologic Diseases in Children

By

Principal Investigator:

Jeff Yu, MD
Massachusetts General Hospital

Overview:

Oral Janus Kinase inhibitors (JAKi) are novel therapeutic options for patients with various inflammatory skin conditions, such as alopecia areata, atopic dermatitis, and psoriasis. Currently, most of the data that exists on the long-term side effects of JAKis comes from the rheumatology literature, where JAKis are used to treat highly inflammatory systemic diseases (i.e. rheumatoid arthritis). There is scant literature on the side effect profile or recommended laboratory monitoring during the use of JAKis in dermatologic conditions. Thus, the purpose of this database will be to provide pediatric dermatologists with accurate safety information and appropriate lab monitoring during the use of JAKis in the treatment of cutaneous inflammatory diseases, such as those listed above.

Status:

This project is new and needs additional sites. If you are interested in joining this study, please contact Hadley Johnson.

The Association Between Psoriasis and Bacterial Infection

By

Principal Investigator:

Esteban Fernandez Faith, MD
Nationwide Children’s Hospital

Overview:

Gut dysbiosis has been implicated in the onset and course of psoriasis, and the gut-skin axis highlights the relationship between the two organs. The association of streptococcal infections and psoriasis has been well documented in the setting of streptococcal respiratory infections, mainly pharyngitis. The relationship between perianal and genital bacterial dermatitis and psoriasis is less well characterized in the literature. We seek to describe the clinical features, treatment regimen, and outcomes of psoriasis associated with pharyngeal or anogenital bacterial infection, with the ultimate goal of enhancing the care of patients affected by psoriasis with this association.

Status:

This study is ongoing and actively seeking collaborators. If you are interested in joining this study as a site, please contact Manisha Ravi or Esteban Fernandez Faith, MD.

Pediatric Contact Dermatitis Registry Using New Baseline Series for Children

By

Principal Investigator:

Jeff Yu, MD
Massachusetts General Hospital

Overview:

Allergic contact dermatitis (ACD) is a delayed-type hypersensitivity reaction. Detection of through patch testing and avoidance of offending allergens are important for resolution of dermatitis. This condition has been underrecognized in children as this was once thought to be rare in children. The true incidence of ACD in children remains unknown due to limited published studies. However, recent data demonstrate the prevalence of ACD in children to be as high as 24%, similar to rates reported in adults. In 2018, a multi-center, prospective pediatric ACD registry was initiated at Massachusetts General Hospital (MGH) in efforts to gather data on the incidence and prevalence of ACD and identify evolving trends of allergen sensitization in children (<18 years old) in North America.

Status:

Eight academic medical centers across North America have joined this registry. If you are interested in joining this study, please contact Dr. Jeff Yu. Data collection is underway across sites. We anticipate publishing our study findings in July 2020 and every two years thereafter.

Sites: